Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevo antídoto sintético para heparina

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOBE20141119001
Publicado:
10/02/2015
Caducidad:
10/02/2016
Resumen:
Un equipo de investigación de una universidad belga ha desarrollado un polímero sintético hemocompatible como alternativa al sulfato de protamina para la neutralización eficiente de heparina. Este polímero presenta una alta afinidad y selectividad para heparinas (fraccionadas y sin fraccionar) en medios biológicos complejos, como plasma humano. El polímero puede administrarse en forma de líquido cuando el diluyente es un medio isotónico o en forma de liofilizado cuando el diluyente es un estabilizador. Se buscan compañías farmacéuticas interesadas en establecer acuerdos de investigación o licencia.

Details

Tittle:
New synthetic antidote for heparin
Summary:
A Belgian university research team developed a synthetic hemocompatible polymer as an alternative to Protamine Sulfate for the rapid and efficient neutralization of heparin.
The researchers are looking for pharmaceutical companies interested in research collaboration or license agreement.
Description:
One key advantage offered by heparin in cardiovascular surgery relies upon its high potency and the availability of an antidote allowing its rapid neutralization. Protamine Sulfate (PS) is the only drug available on the market which can counteract quickly and efficiently the action of heparin. Extracted from fishes, PS, a cationic polypeptide, is made from several sub-units with proportion which can change in number and nature. Moreover its natural source represents a potential risk of persistence of residues, such as heavy metals, endotoxins and other antigenic biological contaminants. More recently, due to fishing restrictions in Japan, the availability issue of PS has raised additional issues. Last and not least, moderate to severe side-effects are observed after its i.v. perfusion with a prevalence of about 11 %. To overcome these problems, the Belgian researchers have developed a synthetic hemocompatible polymer as an alternative to PS for the rapid and efficient neutralization of heparin.
This synthetic polymer consists of a polymer with high affinity and selectivity for heparins (non fractionated and fractionated) in complex biological medium such as human plasma. The polymer can be administered in the form of a liquid wherein the diluent is an isotonic medium or in the form of a lyophilisate wherein the diluent is a stabiliser.
Advantages and Innovations:
-In view of promoting interaction with heparin, the new polymer has an extended structure with a flexible polymer backbone that overcomes the problems of other synthetic polymers with more compact structure.
-The range of concentrations to achieve its pharmacological action is identical to PS. This high potency is linked to its specificity, avoiding non-specific interactions with cellular and humoral compounds present in blood.
-Preclinical assays have demonstrated that the interaction of this polymer with heparin proceeds very quickly (within a time-scale of some minutes).
-Hemocompatible material.
- Easiness to produce on a reproducible way, at an industrial scale and at a very low cost. Its macromolecular characteristics and purity can be easily controlled by macromolecular engineering which allows the adjustment of composition, length and sequence.
Stage of Development:
Available for demonstration
IPs:
Patent(s) applied for but not yet granted

Partner sought

Type and Role of Partner Sought:
Type of Partner:
pharmaceutical companies: the new synthetic antidote is intended to be used as a medicament for the treatment of heparin overdose.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
French

Keywords

Technology Keywords:
06001017 Cirugía
06001011 Enfermedades circulatorias y del corazón
06001015 Productos farmacéuticos / medicamentos